Top 5 Target	Count

50S subunit(50S ribosomal subunit)	2
PBPs(Bacterial penicillin-binding protein)	2
EPO receptor(Erythropoietin receptor)	2
ACE(Angiotensin-converting enzyme)	1
COX x α-adrenergic receptor	1

Drugs associated with Harbin Pharmaceutical Group Co., Ltd.

Omacetaxine Mepesuccinate

Target-

Mechanism

Protein biosynthesis inhibitors

Active Org.

Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd.Startup [+4]

Originator Org.

Teva Pharmaceutical Industries Ltd.

Active Indication

Myelodysplastic Syndromes [+10]

Inactive Indication

Acute Erythroblastic Leukemia [+10]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date26 Oct 2012

Sertraline Citrate

Target

SERT

Mechanism

SERT inhibitors

Active Org.

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

Originator Org.

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

Active Indication

Obsessive-Compulsive Disorder

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date18 Mar 2008

Azithromycin Lactobionate

Target

50S subunit

Mechanism

50S subunit inhibitors

Active Org.

Harbin Pharmaceutical Group Co., Ltd.

Originator Org.

Harbin Pharmaceutical Group Co., Ltd.

Active Indication

Pelvic Inflammatory Disease [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 2001

Clinical Trials associated with Harbin Pharmaceutical Group Co., Ltd.

CTR20232908 / Active, not recruitingNot Applicable

拉西地平片在健康受试者中开放、随机、单剂量、三周期、三序列、部分重复交叉餐后状态下的生物等效性试验

[Translation] An open, randomized, single-dose, three-period, three-sequence, partially repeated crossover bioequivalence study of lacidipine tablets in healthy subjects under the fed state

主要目的:比较餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4mg/片，商品名：Lacipil®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的:评价餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4mg/片，商品名：Lacipil®）的安全性。

[Translation]

Primary objective: To compare the differences in absorption extent and speed of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. in healthy adults under the condition of postprandial administration, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. under the condition of postprandial administration.

Start Date07 Oct 2023

Sponsor / Collaborator

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

CTR20230126 / CompletedNot Applicable

拉西地平片在健康受试者中开放、随机、单剂量、三周期、三序列、部分重复交叉空腹状态下和开放、随机、单剂量、双周期、双交叉餐后状态下的生物等效性试验

[Translation] An open, randomized, single-dose, three-period, three-sequence, partially repeated crossover bioequivalence study of lacidipine tablets in healthy subjects under fasting state and open, randomized, single-dose, two-period, double crossover fed state

主要目的：比较空腹及餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4 mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4 mg/片，商品名：Lacipil®）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的：评价空腹及餐后给药条件下，哈药集团三精明水药业有限公司提供的拉西地平片（4 mg/片）与GLAXOSMITHKLINE,S.A持证的拉西地平片（4 mg/片，商品名：Lacipil®）的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of Lacidipine Tablets (4 mg/tablet) provided by Harbin Pharmaceutical Group Sanjingmingshui Pharmaceutical Co., Ltd. and Lacidipine Tablets (4 mg/tablet, trade name: Lacipil®) licensed by GLAXOSMITHKLINE, S.A. under fasting and postprandial administration conditions.

Start Date14 Feb 2023

Sponsor / Collaborator

Harbin Pharm Group Sanjing Mingshui Pharmaceutical Co., Ltd.

CTR20201628 / CompletedNot Applicable

诺氟沙星片单中心、随机、开放、两周期、两交叉、单次口服给药的人体生物等效性试验

[Translation] A single-center, randomized, open-label, two-period, two-crossover, single oral administration bioequivalence study of norfloxacin tablets in humans

主要目的：观察诺氟沙星片在中国健康受试者中单次口服给药后的诺氟沙星体内动力学过程，估算相应的药代动力学参数，并以杏林制药株式会社生产的诺氟沙星片(Baccidal®)为参比制剂，进行生物等效性评价。次要目的：观察诺氟沙星片（受试制剂）和诺氟沙星片（Baccidal®，参比制剂）在健康人体中的安全性。

[Translation]

Primary objective: To observe the in vivo kinetics of norfloxacin after a single oral administration in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and evaluate the bioequivalence of norfloxacin tablets (Baccidal®) produced by Kyorin Pharmaceutical Co., Ltd. as the reference preparation. Secondary objective: To observe the safety of norfloxacin tablets (test preparation) and norfloxacin tablets (Baccidal®, reference preparation) in healthy humans.

Start Date28 Aug 2020

Sponsor / Collaborator

Harbin Pharmaceutical Group Co., Ltd.

100 Clinical Results associated with Harbin Pharmaceutical Group Co., Ltd.

0 Patents (Medical) associated with Harbin Pharmaceutical Group Co., Ltd.

263

Literatures (Medical) associated with Harbin Pharmaceutical Group Co., Ltd.

01 Oct 2021·Frontiers of MedicineQ3 · MEDICINE

Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

Q3 · MEDICINE

Article

Author: Ni, Li ; Wang, Haisheng ; Li, Chene ; Chen, Yanyan ; Tang, Wei ; Liu, Yujian ; Wen, Zheng ; Wang, Hong ; Weng, Jianping ; Hu, Xiaowen ; Xu, Xizhen ; Li, Dan ; Xiao, Zhichao ; Wang, Dao Wen ; Duan, Jialin ; Li, Jinliang ; Zuo, Jianping ; Yi, Yongxiang ; Zhang, Runhua ; Jiang, Hualiang ; Li, Zongzhe ; Xu, Chang ; Chen, Chen ; Zhao, Jianping ; Huang, Wei ; Wu, Lujin ; Zhou, Ling

We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Patients with 14-day SHL treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests than the patients from the control group (93.4% vs. 73.9%, P = 0.006). Analysis of chest computed tomography images showed that treatment with high-dose SHL significantly promoted absorption of inflammatory focus of pneumonia, which was evaluated by density reduction of inflammatory focus from baseline, at day 7 (mean difference (95% CI), -46.39 (-86.83 to -5.94) HU; P = 0.025) and day 14 (mean difference (95% CI), -74.21 (-133.35 to -15.08) HU; P = 0.014). No serious adverse events occurred in the SHL groups. This study illustrated that SHL in combination with standard care was safe and partially effective for the treatment of COVID-19.

02 Jan 2017·International Journal of Food Sciences and NutritionQ3 · ENGINEERING & TECHNOLOGY

Phytoestrogens and risk of prostate cancer: an updated meta-analysis of epidemiologic studies

Q3 · ENGINEERING & TECHNOLOGY

Review

Author: Wang, Jiaqi ; Qluwakemi, Bakare ; Feng, Hongliang ; Cheng, Guangdong ; Qiu, Hongbin ; Zhang, Qiang ; Zhu, Liling ; Xu, Hui ; Yao, Songpo ; Yuan, Mingxia

This updated meta-analysis was performed to clarify the relationship between phytoestrogens and prostate cancer risk. Twenty one case-control and two cohort studies were finally selected for this meta-analysis, totaling 11,346 cases and 140,177 controls. Analytical results showed that daidzein (OR = 0.85; 95% CI: 0.75-0.96), genistein (OR = 0.87; 95% CI: 0.78-0.98), and glycitein (OR = 0.89; 95% CI: 0.81-0.98) were associated with a reduction of prostate cancer risk, but total isoflavones (OR = 0.93; 95% CI: 0.84-1.04), equol (OR = 0.86; 95% CI: 0.66-1.14), total lignans (OROgna.05; 95% CI: 0.54-2.04), secoisolariciresinol (OR = 1.02; 95% CI: 0.83-1.24), matairesinol (OR = 0.91; 95% CI: 0.75-1.11), enterolactone (OR = 0.94; 95% CI: 0.73-1.20), and coumestrol (OR = 0.89; 95% CI: 0.76-1.06) were not. Sensitivity and publication bias analyses demonstrated that the pooled estimates were stable and reliable. The results support the notion that some phytoestrogens may have a role in decreasing the risk of prostate cancer. Additional large and well-designed cohort studies are needed to confirm these relationships.

01 Dec 2016·Drug Development and Industrial PharmacyQ4 · MEDICINE

The 12-3-12 cationic gemini surfactant as a novel gastrointestinal bioadhesive material for improving the oral bioavailability of coenzyme Q10 naked nanocrystals

Q4 · MEDICINE

Article

Author: Han, Jie ; Zhang, Ting ; Cheng, Xiaobo ; Song, Yanzhi ; Feng, Rui ; Liu, Xinrong ; Deng, Yihui ; Tian, Qingjing ; Wang, Mengjing

To improve the oral bioavailability of nanocrystalline drug preparations, the cationic 12-3-12 quaternary ammonium surfactant gemini was introduced into nanocrystals as a novel gastrointestinal bioadhesive material. Coenzyme Q10 (CoQ10), a typical Biopharmaceutics Classification System (BCS) class II drug, was used as a model drug. The 12-3-12 gemini surfactant was added to the preparation at a low concentration and imbued the particles with abundant positive charges. In vitro and in vivo gastrointestinal adhesion tests confirmed that the gemini-modified nanocrystals were prone to adhere to the upper gastrointestinal tract (GIT), thereby prolonging retention time in the GIT and enhancing absorption. In the distribution study in rats, the use of nanocrystals modified with gemini led to greater drug distribution to the heart and the liver than that achieved with the naked nanocrystals. A pharmacokinetic study in beagle dogs showed that the gemini-modified CoQ10 nanocrystals improved the oral bioavailability of CoQ10 in a dose-dependent manner, and the smaller size produced a much better effect with the same gemini modification. These results demonstrate that the cationic surfactant gemini is a promising oral bioadhesive material with applications in nanoscale drug delivery systems.

News (Medical) associated with Harbin Pharmaceutical Group Co., Ltd.

07 Mar 2024

·www.prnewswire.com

Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Partnering Trends Report 2024: Analysis of Deals Signed by the World's Leading Life Science Companies Signed Since 2016

DUBLIN, March 7, 2024 /PRNewswire/ -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2024" report has been added to ResearchAndMarkets.com's offering. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. Fully revised and updated, the report provides details of co-promotion and co-marketing deals from 2016 to 2024, the report provides access to co-promotion and co-marketing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of co-promotion and co-marketing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of co-promotion and co-marketing deals. Chapter 4 provides a review of the leading co-promotion and co-marketing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active co-promotion and co-marketing dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of co-promotion and co-marketing deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-promotion and co-marketing deal. The deal directory includes a comprehensive listing of all co-promotion and co-marketing deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing alliances. Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits: Understand deal trends since 2016 Browse co-promotion and co-marketing deals Benchmark analysis - identify market value of transactions Financials terms Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology includes: Trends in co-promotion and co-marketing dealmaking in the biopharma industry Overview of co-promotion and co-marketing deal structure Directory of co-promotion and co-marketing deal records covering pharmaceutical and biotechnology The leading co-promotion and co-marketing deals by value Most active co-promotion and co-marketing dealmakers The leading co-promotion and co-marketing partnering resources Analyzing contract agreements allows due diligence of: What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking 2.1. Introduction 2.2. Definition of co-promotion and co-marketing deals 2.3. Trends in co-promotion and co-marketing deals since 2016 2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2024 2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2024 2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2024 2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2024 2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2024 2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2024 2.4. Reasons for entering into co-promotion and co-marketing partnering deals 2.5. The future of co-promotion and co-marketing deals Chapter 3 - Overview of co-promotion and co-marketing deal structure 3.1. Introduction 3.2. Co-promotion and co-marketing agreement structure Chapter 4 - Leading co-promotion and co-marketing deals 4.1. Introduction 4.2. Top co-promotion and co-marketing deals by value Chapter 5 - Top 25 most active co-promotion and co-marketing dealmakers 5.1. Introduction 5.2. Top 25 most active co-promotion and co-marketing dealmakers Chapter 6 - Co-promotion and co-marketing deals including contracts directory 6.1. Introduction 6.2. Co-promotion and co-marketing deals with contracts 2016-2024 Deal directory Deal directory - Co-promotion and co-marketing dealmaking by companies A-Z Deal directory - Co-promotion and co-marketing dealmaking by therapy area Deal directory - Co-promotion and co-marketing dealmaking by technology type Some of the companies featured 3D Medicines 4D Molecular Therapeutics Abbvie AbCellera Biologics ALK-Abello Allegis Pharmaceuticals Allergan Bausch & Lomb Baxalta Bayer Beam Therapeutics BeiGene Beijing Minhai Biotechnology Belharra Therapeutics Belintra Berlin Chemie BioAge Labs Biogen Biognosys Biological Industries BioNano Genomics BioNTech Cipher Pharmaceuticals Concordia Pharmaceuticals CRISPR Therapeutics CrossLink Bioscience CSL Dova Pharmaceuticals Dovetail Genomics DualityBio Eagle Genomics Eagle Pharmaceuticals EA Pharma Eli Lilly Empatica Enterome Bioscience Epizyme Eton Pharmaceuticals Exact Sciences Fabric Genomics Gilead Sciences Glenmark Pharmaceuticals Goldfinch Bio GSK GT Research H3 Biomedicine Halyard Health Hanmi Pharmaceutical Harbin Pharmaceutical Group HD Biosciences Iconic Therapeutics Idorsia IGM Biosciences Illumina Immatics Biotechnologies Immunicon ImmunityBio Ionis Pharmaceuticals Ironwood Pharmaceuticals iTeos Therapeutics Janssen Biotech Janssen Pharmaceuticals Jiangsu Alphamab Konica Minolta Kowa Pharmaceuticals America KSQ Therapeutics Kyorin Pharmaceutical Kyowa Hakko Kirin Kyverna Therapeutics Luqa Pharmaceuticals Luxcel Biosciences Lygos Macrogenics Manchester BIOGEL MannKind Biopharmaceuticals Medicines360 MedImmune Medovate MEI Pharma Menarini Merck and Co Merck KGaA Mersana Therapeutics Mesoblast Metagenomi Metavant Microsoft Nkarta Therapeutics Novartis Novo Nordisk nRichDX Numab Otonomy Otsuka Oxford BioMedica Pacira Biosciences Paragon Bioservices Pfizer Phil Prothena Provention Bio PSI (Population Services International) Purdue Pharma Pure Pharmaceuticals QED Therapeutics Qiagen Quanta Radius Health Rainbow Scientific Rakuten Medical Recludix Pharma RedHill Biopharma RefleXion Medical Regeneron Pharmaceuticals Regenxbio Relay Therapeutics Repare Therapeutics Resonant Specific Technologies Revolution Medicines Rigel Pharmaceuticals Roche Sanofi Seren Pharmaceuticals Seres Therapeutics Shimadzu Shionogi Silicon Biosystems Simcere Pharmaceuticals Sirtex Medical SK Biopharmaceuticals Solid Biosciences Sonoma BioTherapeutics Sosei SparingVision Stealth BioTherapeutics Stoke Therapeutics StrideBio Tango Therapeutics Teijin Telix Pharmaceuticals Terumo Blood and Cell Technologies Tetraphase Pharmaceuticals Teva Pharmaceutical Industries Theravance Thermo Fisher Scientific Tilak Healthcare Tilray Titan Pharmaceuticals Tolmar Urovant Sciences US WorldMeds Verity Pharmaceuticals Vertex Pharmaceuticals Vertice Pharma Vifor Pharma Voyager Therapeutics WAVE Life Sciences Xellia Pharmaceuticals Xencor ZAI Laboratory Zymeworks For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

30 Jun 2022

·www.prnewswire.com

Melatonin Market size to grow by USD 1.49 Bn | Evolving Opportunities with Aspen Pharmacare Holdings Ltd. and B Joshi Agrochem Pharma | Technavio

NEW YORK, June 29, 2022 /PRNewswire/ -- The "Melatonin Market by Product and Geography - Forecast and Analysis 2022-2026" report by Technavio expects the market to observe an incremental growth of USD 1.49 billion between 2021 and 2026, expanding at a CAGR of 14.67% during the forecast period. The report identifies the market to observe maximum growth in North America. The increasing prevalence of sleeping disorders among people is generating high demand for melatonin in the region. Technavio has announced its latest market research report titled Melatonin Market by Product and Geography - Forecast and Analysis 2022-2026 Read Our Report Sample for highlights on the market size, growth momentum, regional growth opportunities, and much more. Market Dynamics The market is driven by the increase in human life expectancy and the number of working hours. Advances in medicine are helping people to live longer. This is resulting in the availability of a larger workforce. The growing work pressure and busy work schedules are forcing people to adopt unhealthy eating habits and give less time to exercise and take part in fitness activities. All these factors have led to a rise in stress and anxiety levels among people. All these factors are increasing the demand for melatonin to relieve stress, thereby driving the growth of the market. In addition, the rise in the geriatric population is anticipated to boost the growth of the melatonin market. However, stringent rules and regulations on the use of melatonin will hamper the growth of the market. Major Vendors in the Melatonin Market: The global melatonin market is concentrated in nature due to the presence of few vendors. The vendors in the market are focusing on the development of cost-effective products to gain a competitive edge. During the forecast period, the competition in the market is expected to intensify owing to innovations and product launches. Technavio identifies the following as dominant players in the market. Aspen Pharmacare Holdings Ltd. B Joshi Agrochem Pharma Biotics Research Corp. BYHEALTH Co. Ltd. Church and Dwight Co. Inc. Harbin Pharmaceutical Group Co. Ltd. Jamieson Wellness Inc. Natrol LLC Nestle SA NOW Health Group Inc. Otsuka Holdings Co. Ltd. Pfizer Inc. Gain more insights into the vendor landscape and other factors influencing the growth of the market. View Report Sample Now Segmentation Analysis Melatonin Market Product Outlook (Revenue, USD Billion, 2021-2026) Pharmaceutical grade melatonin - size and forecast 2021-2026 Food grade melatonin - size and forecast 2021-2026 The demand for pharmaceutical-grade melatonin will be significant during the forecast period. The increasing use of melatonin in treating sleep disorders due to its sedating and calming effect is driving the growth of the segment. Also, the wide availability of melatonin in the form of capsules, tablets, liquid, balms, roll-ons, vaping products, gummies, and others is contributing to the growth of the segment. Melatonin Market Geography Outlook (Revenue, USD Billion, 2021-2026) North America - size and forecast 2021-2026 Europe - size and forecast 2021-2026 APAC - size and forecast 2021-2026 South America - size and forecast 2021-2026 The Middle East and Africa - size and forecast 2021-2026 The North American region will dominate the market growth through the forecast period. The region has a large pool of health-conscious people and patients that suffer from sleep disorders. In addition, factors such as rising standards of living of people, an increase in disposable incomes, the growing awareness about sophisticated self-care systems, and the increase in the number of healthcare facilities are driving the growth of the regional market. Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Read the Sample Report Now Related Reports: Central Nervous System (CNS) Stimulant Drugs Market by Application and Geography - Forecast and Analysis 2022-2026 Traumatic Brain Injury Assessment and Management Devices Market by End-user and Geography - Forecast and Analysis 2022-2026 Table of Contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Product 5.1 Market segments Exhibit 24: Chart on Product - Market share 2021-2026 (%) Exhibit 25: Data Table on Product - Market share 2021-2026 (%) 5.2 Comparison by Product Exhibit 26: Chart on Comparison by Product Exhibit 27: Data Table on Comparison by Product 5.3 Pharmaceutical grade melatonin - Market size and forecast 2021-2026 Exhibit 28: Chart on Pharmaceutical grade melatonin - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Pharmaceutical grade melatonin - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Pharmaceutical grade melatonin - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Pharmaceutical grade melatonin - Year-over-year growth 2021-2026 (%) 5.4 Food grade melatonin - Market size and forecast 2021-2026 Exhibit 32: Chart on Food grade melatonin - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Food grade melatonin - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Food grade melatonin - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Food grade melatonin - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Product Exhibit 36: Market opportunity by Product ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 APAC - Market size and forecast 2021-2026 Exhibit 50: Chart on APAC - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on APAC - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on APAC - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on APAC - Year-over-year growth 2021-2026 (%) 7.6 South America - Market size and forecast 2021-2026 Exhibit 54: Chart on South America - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on South America - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on South America - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on South America - Year-over-year growth 2021-2026 (%) 7.7 Middle East and Africa - Market size and forecast 2021-2026 Exhibit 58: Chart on Middle East and Africa - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Middle East and Africa - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Middle East and Africa - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Middle East and Africa - Year-over-year growth 2021-2026 (%) 7.8 US - Market size and forecast 2021-2026 Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%) 7.9 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 China - Market size and forecast 2021-2026 Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%) 7.12 Japan - Market size and forecast 2021-2026 Exhibit 78: Chart on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on Japan - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on Japan - Year-over-year growth 2021-2026 (%) 7.13 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 Biotics Research Corp. Exhibit 89: Biotics Research Corp. - Overview Exhibit 90: Biotics Research Corp. - Product / Service Exhibit 91: Biotics Research Corp. - Key offerings 10.4 BYHEALTH Co. Ltd. Exhibit 92: BYHEALTH Co. Ltd. - Overview Exhibit 93: BYHEALTH Co. Ltd. - Product / Servic eExhibit 94: BYHEALTH Co. Ltd. - Key offerings 10.5 Church and Dwight Co. Inc. Exhibit 95: Church and Dwight Co. Inc. - Overview Exhibit 96: Church and Dwight Co. Inc. - Business segments Exhibit 97: Church and Dwight Co. Inc. - Key news Exhibit 98: Church and Dwight Co. Inc. - Key offerings Exhibit 99: Church and Dwight Co. Inc. - Segment focus 10.6 Harbin Pharmaceutical Group Co. Ltd. Exhibit 100: Harbin Pharmaceutical Group Co. Ltd. - Overview Exhibit 101: Harbin Pharmaceutical Group Co. Ltd. - Product / Service Exhibit 102: Harbin Pharmaceutical Group Co. Ltd. - Key offerings 10.7 Jamieson Wellness Inc. Exhibit 103: Jamieson Wellness Inc. - Overview Exhibit 104: Jamieson Wellness Inc. - Business segments Exhibit 105: Jamieson Wellness Inc. - Key news Exhibit 106: Jamieson Wellness Inc. - Key offerings Exhibit 107: Jamieson Wellness Inc. - Segment focus 10.8 Natrol LLC Exhibit 108: Natrol LLC - Overview Exhibit 109: Natrol LLC - Product / Service Exhibit 110: Natrol LLC - Key offerings 10.9 Nestle SA Exhibit 111: Nestle SA - Overview Exhibit 112: Nestle SA - Business segments Exhibit 113: Nestle SA - Key news Exhibit 114: Nestle SA - Key offerings Exhibit 115: Nestle SA - Segment focus 10.10 NOW Health Group Inc. Exhibit 116: NOW Health Group Inc. - Overview Exhibit 117: NOW Health Group Inc. - Product / Service Exhibit 118: NOW Health Group Inc. - Key offerings 10.11 Otsuka Holdings Co. Ltd. Exhibit 119: Otsuka Holdings Co. Ltd. - Overview Exhibit 120: Otsuka Holdings Co. Ltd. - Business segments Exhibit 121: Otsuka Holdings Co. Ltd. - Key offerings Exhibit 122: Otsuka Holdings Co. Ltd. - Segment focus 10.12 Pfizer Inc. Exhibit 123: Pfizer Inc. - Overview Exhibit 124: Pfizer Inc. - Product / Service Exhibit 125: Pfizer Inc. - Key news Exhibit 126: Pfizer Inc. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 127: Inclusions checklist Exhibit 128: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 129: Currency conversion rates for US$ 11.4 Research methodology Exhibit 130: Research methodology Exhibit 131: Validation techniques employed for market sizing Exhibit 132: Information sources 11.5 List of abbreviations Exhibit 133: List of abbreviations About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios

Collaborate

16 Jun 2022

·www.globenewswire.com

RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company’s Annual General Meeting. At the Annual General Meeting of the Company held on June 16, 2022 (the AGM), the resolution placed before the meeting in respect of the approval of the waiver under Rule 9 of the Irish Takeover Rules (the Rules) was duly passed by independent shareholders of the Company on a poll. The result of the poll was 28,894,940 votes for; and 1,340,770 votes against. Accordingly, the aggregate percentage shareholding in the capital of the Company held by the parties specified in the table below (and persons deemed to be acting in concert with them under the Rules) (together, the Affected Parties) may proportionally increase up to the maximum percentage specified below in the event of the issue by the Company of up to 17,000,000 new ordinary shares of US$0.01 each in the capital of the Company. In such circumstances, the Affected Parties will not incur an obligation under Rule 9 of the Rules to make a general offer to the Company's other shareholders. Current Shareholding (Number)Current Shareholding (%)Potential Shareholding following Share Issues (%)Avista Healthcare Partners, L.P., and Orbit Co-Invest III LLC16,763,859 ordinary shares20.07%24.64%Altchem Limited and Orbit Co-Invest A-1 LLC23,667,540 ordinary shares28.34%31.51%Management Individuals (as defined in the Proxy Statement)2,115,895 ordinary shares2.53%3.1% The full text of the resolution (being Proposal 3) is set out in the Proxy Statement in respect of the AGM which is available at https://www.rvlpharma.com/. About RVL Pharmaceuticals plc RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Investor and Media Relations for RVL Pharmaceuticals plc Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com

100 Deals associated with Harbin Pharmaceutical Group Co., Ltd.

100 Translational Medicine associated with Harbin Pharmaceutical Group Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Deserpidine/Methyclothiazide ( NCC )	Hypertension More	Approved
Recombinant human erythropoietin (CHO Cell), Harbin Pharmaceutical Group Bioengineering(Harbin Pharmaceutical Group Co., Ltd.) ( EPO receptor )	Anemia More	Approved
Methoxyphenamine Hydrochloride ( β-adrenoceptors )	Asthma More	Approved
Recombinant human granulocyte colony-stimulating factor(Harbin Pharmaceutical Group Co., Ltd.) ( CSF-3R )	Neutropenia More	Approved
Omacetaxine Mepesuccinate	Polycythemia Vera More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis